Boston Scientific Corporation (BSX) : Diamond Hill Capital Management Inc scooped up 739,511 additional shares in Boston Scientific Corporation during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 12, 2016. The investment management firm now holds a total of 20,339,317 shares of Boston Scientific Corporation which is valued at $454.6 Million.Boston Scientific Corporation makes up approximately 2.92% of Diamond Hill Capital Management Inc’s portfolio.
Other Hedge Funds, Including , Bb&t Securities sold out all of its stake in BSX during the most recent quarter. The investment firm sold 84,393 shares of BSX which is valued $1.9 Million.Anchor Capital Advisors reduced its stake in BSX by selling 136,276 shares or 4.44% in the most recent quarter. The Hedge Fund company now holds 2,934,367 shares of BSX which is valued at $65.6 Million. Boston Scientific Corporation makes up approx 1.67% of Anchor Capital Advisors’s portfolio.State Board Of Administration Of Florida Retirement System reduced its stake in BSX by selling 47,850 shares or 2.66% in the most recent quarter. The Hedge Fund company now holds 1,747,994 shares of BSX which is valued at $38.5 Million. Boston Scientific Corporation makes up approx 0.15% of State Board Of Administration Of Florida Retirement System’s portfolio.Cibc World Markets reduced its stake in BSX by selling 68,185 shares or 83.68% in the most recent quarter. The Hedge Fund company now holds 13,300 shares of BSX which is valued at $292,999. Raveneur Investment Group Lp added BSX to its portfolio by purchasing 875,792 company shares during the most recent quarter which is valued at $19.3 Million. Boston Scientific Corporation makes up approx 9.59% of Raveneur Investment Group Lp’s portfolio.
Boston Scientific Corporation opened for trading at $22.29 and hit $22.52 on the upside on Friday, eventually ending the session at $22.37, with a gain of 0.90% or 0.2 points. The heightened volatility saw the trading volume jump to 85,33,288 shares. Company has a market cap of $30,353 M.
On the company’s financial health, Boston Scientific Corporation reported $0.28 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on Apr 27, 2016. Analyst had a consensus of $0.24. The company had revenue of $1964.00 million for the quarter, compared to analysts expectations of $1912.86 million. The company’s revenue was up 11.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.21 EPS.
Many Wall Street Analysts have commented on Boston Scientific Corporation. Company shares were Reiterated by RBC Capital Mkts on Apr 28, 2016 to “Outperform”, Firm has raised the Price Target to $ 25 from a previous price target of $22 .Company shares were Reiterated by Stifel on Apr 28, 2016 to “Buy”, Firm has raised the Price Target to $ 25 from a previous price target of $22 .Company shares were Reiterated by Wedbush on Apr 28, 2016 to “Neutral”, Firm has raised the Price Target to $ 23 from a previous price target of $19 .
Boston Scientific Corporation develops manufactures and markets medical devices. The Company offers its products by seven core businesses: Interventional Cardiology which includes Drug-Eluting Coronary Stent Systems Intravascular Imaging devised and Coronary Technology products such as guide wires guide catheters and balloon catheters among others; Peripheral Interventions (PI) which include stents balloon catheters wires peripheral embolization devices and vena cava filters; Cardiac Rhythm Management (CRM) which include implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities; Electrophysiology (EP) which include steerable RF ablation catheters intracardiac ultrasound catheters diagnostic catheters delivery sheaths and other accessories; Endoscopy which includes Spyglass System WallFlex Colonic Stents Resolution Clip and Expect Aspiration Needle among others; Urology and Womens Health and Neuromodulation.